The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases
Open accessAbstract
Histone deacetylase 8 (HDAC8), a unique class I zinc-dependent HDAC, is an emerging target in cancer and other diseases. Its substrate repertoire extends beyond histones to many nonhistone proteins. Besides being a deacetylase, HDAC8 also mediates signaling via scaffolding functions. Aberrant expression or deregulated interactions with transcription factors are critical in HDAC8-dependent cancers. Many potent HDAC8-selective inhibitors with cellular activity and anticancer effects have been reported. We present HDAC8 as a druggable target and discuss inhibitors of different chemical scaffolds with cellular effects. Furthermore, we review HDAC8 activators that revert activity of mutant enzymes. Isotype-selective HDAC8 targeting in patients with HDAC8-relevant cancers is challenging, however, is promising to avoid adverse side effects as observed with pan-HDAC inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Histone deacetylase 8 expression in normal and tumor cells. R2 MegaSampler [66] with HDAC8 probe 223345_at. (A) HDAC8 expression of normal B cells (N1-2, blue), leukocytes (N3, blue) and expression in AML (1-8, green) and ALL (1-5, orange). (B) Normal (blue) colon (N1) expression compared with expression in colon cancer (T Colon 1-15, red). (C) Normal neural crest (N1, blue) expression compared with expression in neuroblastoma (1-4). (D) Normal neural crest (N1, blue) expression compared with expression in neuroblastoma INSS stage 4 and stage 4s samples of the Versteeg (1), Delattre (2), Hiyama (3) and Latowska (4) cohort. ALL: Acute lymphocytic leukemia; AML: Acute myeloid leukemia; HDAC8: Histone deacetylase 8.](https://figures.cochat.ai/paper-figures/e4cf4484a2ed428fa009973f11b9c76a/targeting-histone-deacetylase-8-as-a-therapeutic-approach-to-cancer-and-figure-2.png)







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“an HDAC isozyme that has been shown to be overexpressed in several cancers 19-21”
From Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Chao, M., Chu, P., Chuang, H.-C., Shen, F.-H., Chou, C.-C., Hsu, E., Himmel, L. E., Huang, H.-L., Tu, H., Kulp, S. K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6427 · Cited by 32
RetractedWang, Y., Xu, P., Yao, J., Yang, R., Shi, Z., Zhu, X., Feng, X., & Gao, S. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0390-9 · Cited by 18
RetractedLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Self-citationKelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
Cited by
Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms
Dadashpour, S., & Emami, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.065 · Cited by 343
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Liu, T., Wan, Y., Xiao, Y., Xia, C., & Duan, G. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00491 · Cited by 186
Next-generation of selective histone deacetylase inhibitors
Yang, F., Zhao, N., Ge, D., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra02985k · Cited by 154
Marek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01087 · Cited by 122
Self-citationStrategies To Design Selective Histone Deacetylase Inhibitors
Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021) · ChemMedChem · doi:10.1002/cmdc.202000934 · Cited by 118
Self-citationHistone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview
Banerjee, S., Adhikari, N., Amin, S. A., & Jha, T. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.039 · Cited by 127
Heimburg, T., Kolbinger, F. R., Zeyen, P., Ghazy, E., Herp, D., Schmidtkunz, K., Melesina, J., Shaik, T. B., Erdmann, F., Schmidt, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01447 · Cited by 92
Self-citationLong, J., Jia, M.-Y., Fang, W.-Y., Chen, X.-J., Mu, L.-L., Wang, Z.-Y., Shen, Y., Xiang, R.-F., Wang, L.-N., Wang, L., et al. (2020) · Blood · doi:10.1182/blood.2019003538 · Cited by 84
Curcio, A., Rocca, R., Alcaro, S., & Artese, A. (2024) · Pharmaceuticals · doi:10.3390/ph17050620 · Cited by 80
Amin, S. A., Adhikari, N., & Jha, T. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.002 · Cited by 74
Zhang, R., Shen, M., Wu, C., Chen, Y., Lu, J., Li, J., Zhao, L., Meng, H., Zhou, X., Huang, G., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03212-3 · Cited by 69
Hua, W.-K., Qi, J., Cai, Q., Carnahan, E., Ayala Ramirez, M., Li, L., Marcucci, G., & Kuo, Y.-H. (2017) · Blood · doi:10.1182/blood-2017-03-771386 · Cited by 57
Upadhyay, N., Tilekar, K. N., Jänsch, N., Schweipert, M., Hess, J. D., Macias, L. G.-F., Mrówka, P., Aguilera, R. J., Choe, J., Meyer‐Almes, F., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103934 · Cited by 56
Tilekar, K. N., Upadhyay, N., Jänsch, N., Schweipert, M., Mrówka, P., Meyer‐Almes, F., & Ramaa, C. S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103522 · Cited by 52
Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents
Amin, S. A., Adhikari, N., & Jha, T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.001 · Cited by 53
The enzyme activity of histone deacetylase 8 is modulated by a redox-switch
Jänsch, N., Meyners, C., Muth, M., Kopranovic, A., Witt, O., Oehme, I., & Meyer‐Almes, F. (2018) · Redox Biology · doi:10.1016/j.redox.2018.09.013 · Cited by 51
Self-citationSun, P., Wang, J., Khan, K. S., Yang, W., Ng, W., Ilment, N. V., Zessin, M., Bülbül, E. F., Robaa, D., Erdmann, F., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01132 · Cited by 50
Self-citationA Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
Fontana, A., Cursaro, I., Carullo, G., Gemma, S., Butini, S., & Campiani, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710014 · Cited by 47
Darwish, S., Ghazy, E., Heimburg, T., Herp, D., Zeyen, P., Salem-Altintas, R., Ridinger, J., Schmidtkunz, K., Robaa, D., Erdmann, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147535 · Cited by 48
Self-citationSmall molecules as tools to study the chemical epigenetics of lysine acetylation
Schiedel, M., & Conway, S. J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.015 · Cited by 47
Amin, S. A., Adhikari, N., & Jha, T. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0130 · Cited by 45
The role of protein acetylation in carcinogenesis and targeted drug discovery
Yang, J., Song, C., & Zhan, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.972312 · Cited by 42
Discovery of highly potent HDAC8 PROTACs with anti-tumor activity
Zhao, C., Chen, D., Suo, F., Setroikromo, R., Quax, W. J., & Dekker, F. J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106546 · Cited by 41
Wang, Y. F., Liu, F., Sherwin, S. K., Farrelly, M. L., Yan, X. G., Croft, A. J., Liu, T., Jin, L., Zhang, X. D., & Jiang, C. C. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.11.009 · Cited by 42
Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors
Zhao, C., Zang, J., Ding, Q., Inks, E. S., Xu, W., Chou, C. J., & Zhang, Y. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.002 · Cited by 40
Lagunes, I., Begines, P., Silva, A., Galán, A. R., Puerta, A., Fernandes, M. X., Maya, I., Fernández‐Bolaños, J. G., López, Ó., & Padrón, J. M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.073 · Cited by 38
Designing HDAC-PROTACs: Lessons Learned So Far
Fischer, F., Avelar, L. A. A., Murray, L., & Kurz, T. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0206 · Cited by 38
Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD)
Bourguet, E., Ozdarska, K., Moroy, G., Jeanblanc, J., & Naassila, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00115 · Cited by 36
Wolff, B., Jänsch, N., Sugiarto, W. O., Frühschulz, S., Lang, M., Altintas, R., Oehme, I., & Meyer‐Almes, F. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111756 · Cited by 34
Self-citationPantelaiou‐Prokaki, G., Mieczkowska, I. K., Schmídt, G., Fritzsche, S., Prokakis, E., Gallwas, J. K. S., & Wegwitz, F. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01228-4 · Cited by 35
Diverse Classes of HDAC8 Inhibitors: In Search of Molecular Fingerprints that Regulate Activity
Amin, S. A., Adhikari, N., & Jha, T. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0005 · Cited by 35
Amin, S. A., Khatun, S., Gayen, S., Das, S., & Jha, T. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115594 · Cited by 34
Cho, H.-R., Son, W.-C., Lee, Y.-S., Youn, E. J., Kang, C., Park, Y.-S., & Bae, J. (2021) · Molecules · doi:10.3390/molecules26133952 · Cited by 30
Selective and Nonselective HDAC8 Inhibitors: a Therapeutic Patent Review
Adhikari, N., Amin, S. A., & Jha, T. (2018) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2018-0019 · Cited by 32
Mahajan, M., Suryavanshi, S., Bhowmick, S., Alasmary, F. A., Almutairi, T. M., Islam, M. A., & Kaul-Ghanekar, R. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106588 · Cited by 28
Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group
He, J., Wang, S., Liu, X., Lin, R., Deng, F., Jia, Z., Zhang, C., Zhao, L., Zhu, H., Tang, L., et al. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00256 · Cited by 27
Amin, S. A., Adhikari, N., & Jha, T. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1661876 · Cited by 25
HDAC8 as a target in drug discovery: Function, structure and design
Zhao, Q., Liu, H., Peng, J., Niu, H., Liu, J., Xue, H., Liu, W., Liu, X., Hao, H., Zhang, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116972 · Cited by 25
Pietro, A. D., & Good‐Jacobson, K. L. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800137 · Cited by 24
Uba, A. İ., Weako, J., Keskin, Ö., Gürsoy, A., & Yelekçi, K. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1615989 · Cited by 24
Evaluation of Novel 3-Hydroxyflavone Analogues as HDAC Inhibitors against Colorectal Cancer
Biswas, S., Reddy, N. D., Jayashree, B. S., & Rao, C. M. (2018) · Advances in Pharmacological Sciences · doi:10.1155/2018/4751806 · Cited by 23
Muth, M., Jänsch, N., Kopranovic, A., Krämer, A., Wössner, N., Jung, M., Kirschhöfer, F., Brenner‐Weiß, G., & Meyer‐Almes, F. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.01.001 · Cited by 23
Self-citationDutta, S., Halder, A. K., Adhikari, N., Amin, S. A., Das, S., Saha, A., & Jha, T. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0361 · Cited by 22
The clinical significance of histone deacetylase-8 in human breast cancer
Rahmani, G., Sameri, S., Abbasi, N., Abdi, M., & Najafi, R. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153396 · Cited by 22
Herp, D., Ridinger, J., Robaa, D., Shinsky, S. A., Schmidtkunz, K., Yesiloglu, T. Z., Bayer, T., Steimbach, R. R., Herbst‐Gervasoni, C. J., Merz, A., et al. (2022) · ChemBioChem · doi:10.1002/cbic.202200180 · Cited by 22
Self-citationZhao, C., Zhang, J., Zhou, H., Setroikromo, R., Poelarends, G. J., & Dekker, F. J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00836 · Cited by 21
Kashyap, K., & Kakkar, R. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1567388 · Cited by 20
Banerjee, S., Adhikari, N., Amin, S. A., & Jha, T. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1617782 · Cited by 21
Yuliana, A., Jheng, H., Kawarasaki, S., Nomura, W., Takahashi, H., Ara, T., Kawada, T., & Goto, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082436 · Cited by 17
Kashyap, K., & Kakkar, R. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.103850 · Cited by 18
Kashyap, K., & Kakkar, R. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1711191 · Cited by 17
Ko, H.-J., Chiou, S.-J., Tsai, C.-Y., Loh, J., Lin, X., Tran, T.-H., Hou, C.-C., Cheng, T., Lai, J.-M., Chang, P. M., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-01007-x · Cited by 16
HDAC8 As an Emerging Target in Drug Discovery With Special Emphasis on Medicinal Chemistry
Rajaraman, S., Balakrishnan, R., Deshmukh, D., Ganorkar, A., Biswas, S., Pulya, S., & Ghosh, B. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0054 · Cited by 16
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)
Banerjee, S., Ghosh, B., Jha, T., & Adhikari, N. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2391289 · Cited by 15
Exploration of histone deacetylase 8 inhibitors through classification QSAR study: Part II
Amin, S. A., Adhikari, N., & Jha, T. (2019) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2019.127529 · Cited by 15
Zhang, M., Ying, J. B., Wang, S., He, D., Zhu, H., Zhang, C., Tang, L., Lin, R., & Zhang, Y. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29583 · Cited by 15
Corroborating evidence for aberrant expression of histone deacetylase 8 in endometriosis
Zheng, H., Liu, X., & Guo, S. (2023) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12527 · Cited by 14
Dewaker, V., Srivastava, P. N., Verma, S. K., & Prabhakar, Y. S. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1598497 · Cited by 14
Banerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1704881 · Cited by 13
Approaches for discovering novel bioactive small molecules targeting autophagy
Hwang, H., Cho, S. M., & Kwon, H. J. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1349751 · Cited by 13
Zheng, H., Liu, X., & Guo, S. (2023) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12531 · Cited by 12
González, F. P. G., & Mancilla, T. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104080 · Cited by 12
Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment
Hussain, M. S., Zhang, L., Rana, A. J., Maqbool, M., Ashique, S., Khan, Y., Jakhmola, V., Hanbashi, A., Mawkili, W., & Khan, G. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2533113 · Cited by 11
Banerjee, S., Baidya, S. K., Adhikari, N., & Jha, T. (2022) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2022.2155241 · Cited by 11
Chang, T.-Y., Yan, Y., Yu, Z.-Y., Rathore, M. G., Lee, N.-Z., Tseng, H.-J., Cheng, L.-H., Huang, W., Zhang, W., Chan, E. R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci165448 · Cited by 11
Switching the Switch: Ligand Induced Disulfide Formation in HDAC8
Jänsch, N., Sugiarto, W. O., Muth, M., Kopranovic, A., Desczyk, C., Ballweg, M., Kirschhöfer, F., Brenner‐Weiß, G., & Meyer‐Almes, F. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202001712 · Cited by 11
Binding mechanism and distant regulation of histone deacetylase 8 by PCI-34051
Luo, Y., Yan, Z., Chu, X., Zhang, Y., Qiu, Y., & Li, H. (2025) · Communications Biology · doi:10.1038/s42003-025-07649-0 · Cited by 11
Moinul, M., Amin, S. A., Khatun, S., Das, S., Jha, T., & Gayen, S. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133967 · Cited by 10
The nature of the GRE influences the screening for GR-activity enhancing modulators
Dendoncker, K., Timmermans, S., Looveren, K. V., Cauwer, L. D., Bosscher, K. D., & Libert, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181101 · Cited by 9
Amin, S. A., Banerjee, S., Adhikari, N., & Jha, T. (2020) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2020.1723136 · Cited by 9
Zalloum, W. A., & Zalloum, N. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c01696 · Cited by 9
Jänsch, N., Lang, K. L., & Meyer‐Almes, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911775 · Cited by 9
Li, Y., Liu, S., Xu, X., Xu, J., Yang, L., & Hu, L. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2272751 · Cited by 8
The role of histone deacetylases in inflammatory respiratory diseases: an update
Pan, S., Wang, X., Jiao, J., & Zhang, L. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2363803 · Cited by 8
Discovery of organosulfur-based selective HDAC8 inhibitors with anti-neuroblastoma activity
Cho, H., Lee, E., Kim, J., Shin, S., Kim, Y. J., Lee, H., Yu, J. H., Jeon, Y. H., Lee, S. W., Lee, S. Y., et al. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106921 · Cited by 7
A degradation product of PD 404182 (P2742) bound to Histone Deacetylase-like Amidohydrolase
Kraemer, A., & Meyer‐Almes, F. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6gjk/pdb · Cited by 7
Ganai, S. A., Shah, M. D., Dar, S. R., & Padder, S. A. (2024) · The Nucleus · doi:10.1007/s13237-024-00503-4 · Cited by 6
Acetanilide and bromoacetyl-lysine derivatives as activators for human histone deacetylase 8
Mukhtar, Y. M., Huang, Y., Liu, J., Chen, D., & Zheng, W. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.037 · Cited by 5
Kozlov, M. V., Malikova, A. Z., Kamarova, K. A., Konduktorov, K. A., & Kochetkov, S. N. (2018) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162018040118 · Cited by 6
Alrouji, M., Venkatesan, K., Alshammari, M. S., Alhumaydhi, F. A., Shafi, S., Sharaf, S. E., Shahwan, M. J., & Shamsi, A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1488585 · Cited by 4
Recommended Tool Compounds: Isoform- and Class-Specific Histone Deacetylase Inhibitors
Schäker‐Hübner, L., & Hansen, F. K. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00619 · Cited by 5
Replacement of the hydroxamic acid group in the selective HDAC8 inhibitor PCI-34051
Long, K. E., Close, D. A., Johnston, P. A., & Huryn, D. M. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129810 · Cited by 4
González, F. P. G., Pérez, M. E. M., Cortés, O. R., Jiménez, E. M., & Mancilla, T. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70098 · Cited by 4
Kollár, J., & Frecer, V. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.08.008 · Cited by 4
Peng, Y., Gao, Q., Wang, Y., Yao, Q., & Zhang, J. (2021) · ChemMedChem · doi:10.1002/cmdc.202001004 · Cited by 4
Targeting cancers and metabolic disorders: The prospects of combining HDAC8 inhibitor and activator
Yusif, M. M. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100097 · Cited by 5
A Versatile Strategy for Screening Custom‐Designed Warhead‐Armed Cyclic Peptide Inhibitors
Kang, D., Kim, D.-W., Kim, J., & Park, H. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202214815 · Cited by 5
Zhai, S., Kemkes, M., Kponomaizoun, C.-E., Gerhartz, J., Feller, F., Tu, J., Pieńkowska, D. E., Schliehe‐Diecks, J., Dressel, I., Gütschow, M., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00939 · Cited by 3
Morales-Herrejón, G., Mendoza-Figueroa, H. L., Martínez‐Archundia, M., & Correa‐Basurto, J. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206299644240523054454 · Cited by 3
Aljaar, N., Qaderi, M. A., Mansi, I. A., Shtaiwi, M., Alhmaideen, A. I., Al‐Refaib, M., Al-Noaimi, M. Z., Abu‐Irmaileh, B., Kant, K., & Malakar, C. C. (2025) · ChemistrySelect · doi:10.1002/slct.202502223 · Cited by 2
Herp, D., Ridinger, J., Robaa, D., Shinsky, S. A., Schmidtkunz, K., Yesiloglu, T. Z., Bayer, T., Sehr, P. A., Gunkel, N., Miller, A. K., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12440096.v3 · Cited by 2
Self-citationRamírez, J. E. G., & Mancilla, T. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14323 · Cited by 1
Banerjee, S., Baidya, S. K., Jha, T., Ghosh, B., & Adhikari, N. (2024) · Medicinal Chemistry · doi:10.2174/0115734064329669241007060848 · Cited by 1
Zhao, Y., Zhang, M., Liang, Z., Liu, X., Kong, W., Hu, L., Zhou, Y., Lv, K., Zhao, M., Chen, D., et al. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143787 · Cited by 1
Garcia-Franco, P. M., Falcó-Martí, F. J., Jeblaoui, H., del Rio, M. A., Ortega-Alarcón, D., Vega, S., Galano-Frutos, J. J., Abián, O., & Velázquez‐Campoy, A. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149851 · Cited by 1
Banerjee, S., Adhikari, N., & Ghosh, B. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00871a · Cited by 1
Targeted HDAC8 inhibition with non-hydroxamate [1,2,4]triazolo[4,3-a] quinoline compounds
Bandaru, N. V. M. R., Fathima, A., Sengar, S., Schweipert, M., Chaitanya, K. S., Mohammed, M.-U.-R., Gore, S. T., Trinath, J., Sharma, V., Abbineni, C., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-38490-y · Cited by 1
Docking belinostat into HDAC 8 using autodock tool
Thao, H. N., De, T., Hue, B. T. B., Tuan, N. T., Bach, L. T., Quoc, N. C., Si, N. T., Toan, N. H., & Quy, H. T. K. (2020) · Can Tho University Journal of Science · doi:10.22144/ctu.jen.2020.009 · Cited by 1
Ganai, S. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-8179-3_11 · Cited by 2
A Versatile Strategy for Screening Custom‐Designed Warhead‐Armed Cyclic Peptide Inhibitors
Kang, D., Kim, D.-W., Kim, J., & Park, H. (2022) · Angewandte Chemie · doi:10.1002/ange.202214815 · Cited by 1
Metadata
- Authors
- Chakrabarti, A., Melesina, J., Kolbinger, F. R., Oehme, I., Senger, J., Witt, O., Sippl, W., & Jung, M.
- Affiliations
- University of Freiburg (DE)
- Martin Luther University Halle-Wittenberg (DE)
- German Cancer Research Center (DE)
- Venue
- Future Medicinal Chemistry
- Publisher
- Informa UK Limited
- Published
- 2016-08-30
- Volume
- 8
- Issue
- 13
- Pages
- 1609-1634
- ISSN
- 1756-8919 (ISSN-L)
- 1756-8927
- OpenAlex
- W2510695850
- Cited by
- 111
- References
- 127
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 12 · 2023: 8 · 2022: 14 · 2021: 8 · 2020: 15 · 2019: 14 · 2018: 14 · 2017: 9
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Future Medicinal Chemistry (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Funders
- H.W. & J Hector foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- HDAC8, HDAC8 inhibitors, class I HDACs, transcription factor interaction, cancer therapy, neurodegenerative diseases
- MeSH terms
- Antineoplastic Agents, Histone Deacetylases, Humans, Neoplasms, Repressor Proteins, Neuroprotective Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.